ONTOLOGY REPORT - ANNOTATIONS
| Term: | fluoxetine |
|
| Accession: | CHEBI:5118
|
browse the term
|
| Definition: | A benzenoid aromatic compound that has formula C17H18F3NO. |
| Synonyms: | exact_synonym: | N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine |
| | related_synonym: | (+-)-N-methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine; (+-)-N-methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine; C17H18F3NO; CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1; InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3; InChIKey=RTHCYVBBDHJXIQ-UHFFFAOYSA-N; Prozac; fluoxetina; fluoxetinum |
| | xref_casrn: | 54910-89-3 |
| | xref: | Beilstein:39914106 "Beilstein Registry Number"; ChEMBL:102223 "ChEMBL COMPOUND"; ChemIDplus:54910-89-3 "CAS Registry Number"; DrugBank:DB00472 "DrugBank"; KEGG DRUG:54910-89-3 "CAS Registry Number"; KEGG DRUG:D00326 "KEGG DRUG" |
| | xref_mesh: | MESH:D005473 |
| | xref: | Patent:DE2500110 "Patent"; Patent:US4314081 "Patent"; Wikipedia:Fluoxetine "Wikipedia" |
|
|
fluoxetine
|
| G |
Aanat |
aralkylamine N-acetyltransferase |
|
increases expression |
EXP |
10 |
106,709,371 |
106,713,683 |
RGD:6480464 |
CTD |
| G |
Aanat |
aralkylamine N-acetyltransferase |
|
increases expression |
EXP |
10 |
106,709,371 |
106,713,683 |
RGD:6480464 |
CTD |
| G |
Acp5 |
acid phosphatase 5, tartrate resistant |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Adam10 |
ADAM metallopeptidase domain 10 |
|
increases expression |
EXP |
8 |
75,200,657 |
75,289,572 |
RGD:6480464 |
CTD |
| G |
Adarb1 |
adenosine deaminase, RNA-specific, B1 |
|
multiple interactions |
ISO |
20 |
11,616,718 |
11,747,294 |
RGD:6480464 |
CTD |
| G |
Adarb1 |
adenosine deaminase, RNA-specific, B1 |
|
increases expression |
ISO |
20 |
11,616,718 |
11,747,294 |
RGD:6480464 |
CTD |
| G |
Adcy8 |
adenylate cyclase 8 (brain) |
|
decreases expression |
EXP |
7 |
101,957,807 |
102,210,346 |
RGD:6480464 |
CTD |
| G |
Amelx |
amelogenin, X-linked |
|
decreases expression |
ISO |
X |
45,763,451 |
45,769,374 |
RGD:6480464 |
CTD |
| G |
Ano3 |
anoctamin 3 |
|
decreases expression |
EXP |
3 |
96,123,925 |
96,237,157 |
RGD:6480464 |
CTD |
| G |
Anp32a |
acidic (leucine-rich) nuclear phosphoprotein 32 family, member A |
|
decreases expression |
EXP |
8 |
66,488,188 |
66,523,421 |
RGD:6480464 |
CTD |
| G |
Anxa1 |
annexin A1 |
|
decreases expression |
EXP |
1 |
223,478,436 |
223,494,455 |
RGD:6480464 |
CTD |
| G |
Anxa5 |
annexin A5 |
|
multiple interactions |
ISO |
2 |
122,949,210 |
122,979,757 |
RGD:6480464 |
CTD |
| G |
Anxa5 |
annexin A5 |
|
affects expression |
EXP |
2 |
122,949,210 |
122,979,757 |
RGD:6480464 |
CTD |
| G |
Ap1s1 |
adaptor-related protein complex 1, sigma 1 subunit |
|
decreases expression |
ISO |
12 |
20,907,855 |
20,918,301 |
RGD:6480464 |
CTD |
| G |
Arc |
activity-regulated cytoskeleton-associated protein |
|
increases expression |
EXP |
7 |
112,771,937 |
112,775,381 |
RGD:6480464 |
CTD |
| G |
Arc |
activity-regulated cytoskeleton-associated protein |
|
decreases expression |
EXP |
7 |
112,771,937 |
112,775,381 |
RGD:6480464 |
CTD |
| G |
Arc |
activity-regulated cytoskeleton-associated protein |
|
increases expression |
EXP |
7 |
112,771,937 |
112,775,381 |
RGD:6480464 |
CTD |
| G |
Arl4d |
ADP-ribosylation factor-like 4D |
|
increases expression |
EXP |
10 |
90,700,469 |
90,702,625 |
RGD:6480464 |
CTD |
| G |
Arntl |
aryl hydrocarbon receptor nuclear translocator-like |
|
increases expression |
ISO |
1 |
171,062,181 |
171,162,426 |
RGD:6480464 |
CTD |
| G |
Arrb1 |
arrestin, beta 1 |
|
multiple interactions |
ISO |
1 |
156,871,564 |
156,937,540 |
RGD:6480464 |
CTD |
| G |
Arrb2 |
arrestin, beta 2 |
|
multiple interactions |
ISO |
10 |
57,244,071 |
57,284,166 |
RGD:6480464 |
CTD |
| G |
Arrb2 |
arrestin, beta 2 |
|
increases response to substance |
ISO |
10 |
57,244,071 |
57,284,166 |
RGD:6480464 |
CTD |
| G |
Asah1 |
N-acylsphingosine amidohydrolase (acid ceramidase) 1 |
|
increases expression |
ISO |
16 |
54,279,253 |
54,311,084 |
RGD:6480464 |
CTD |
| G |
Asah1 |
N-acylsphingosine amidohydrolase (acid ceramidase) 1 |
|
increases expression |
ISO |
16 |
54,279,253 |
54,311,084 |
RGD:6480464 |
CTD |
| G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
|
increases expression |
ISO |
4 |
32,758,866 |
32,776,220 |
RGD:6480464 |
CTD |
| G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
|
increases expression |
ISO |
4 |
32,758,866 |
32,776,220 |
RGD:6480464 |
CTD |
| G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
|
increases expression |
ISO |
4 |
32,758,866 |
32,776,220 |
RGD:6480464 |
CTD |
| G |
Atp2a2 |
ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 |
|
increases expression |
EXP |
12 |
35,266,600 |
35,316,237 |
RGD:6480464 |
CTD |
| G |
Avp |
arginine vasopressin |
|
decreases expression |
EXP |
3 |
118,205,007 |
118,206,985 |
RGD:6480464 |
CTD |
| G |
Bad |
BCL2-associated agonist of cell death |
|
increases expression |
ISO |
1 |
209,617,373 |
209,626,292 |
RGD:6480464 |
CTD |
| G |
Baiap2 |
BAI1-associated protein 2 |
|
decreases expression |
EXP |
10 |
109,351,201 |
109,413,703 |
RGD:6480464 |
CTD |
| G |
Bcl11b |
B-cell CLL/lymphoma 11B (zinc finger protein) |
|
decreases expression |
EXP |
6 |
132,292,671 |
132,384,572 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
decreases response to substance |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
decreases expression |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
decreases expression |
EXP |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
increases expression |
EXP |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
affects expression |
EXP |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
decreases expression |
EXP |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
increases response to substance |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
decreases response to substance |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
increases response to substance |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
affects response to substance |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
affects expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
decreases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Becn1 |
beclin 1, autophagy related |
|
increases expression |
ISO |
10 |
90,317,957 |
90,333,329 |
RGD:6480464 |
CTD |
| G |
Bet1l |
Bet1 golgi vesicular membrane trafficking protein-like |
|
increases expression |
EXP |
1 |
201,010,734 |
201,013,527 |
RGD:6480464 |
CTD |
| G |
Bmpr2 |
bone morphogenetic protein receptor, type II (serine/threonine kinase) |
|
multiple interactions |
EXP |
9 |
58,327,587 |
58,436,057 |
RGD:6480464 |
CTD |
| G |
Brs3 |
bombesin-like receptor 3 |
|
decreases expression |
EXP |
X |
141,688,650 |
141,693,028 |
RGD:6480464 |
CTD |
| G |
C1ql3 |
complement component 1, q subcomponent-like 3 |
|
decreases expression |
EXP |
17 |
87,275,167 |
87,285,484 |
RGD:6480464 |
CTD |
| G |
Cacna1g |
calcium channel, voltage-dependent, T type, alpha 1G subunit |
|
affects expression |
EXP |
10 |
83,043,636 |
83,112,886 |
RGD:6480464 |
CTD |
| G |
Cacna1h |
calcium channel, voltage-dependent, T type, alpha 1H subunit |
|
decreases expression |
EXP |
10 |
14,621,372 |
14,679,051 |
RGD:6480464 |
CTD |
| G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
|
decreases expression |
EXP |
18 |
25,404,123 |
25,625,785 |
RGD:6480464 |
CTD |
| G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
|
multiple interactions |
EXP |
18 |
25,404,123 |
25,625,785 |
RGD:6480464 |
CTD |
| G |
Cartpt |
CART prepropeptide |
|
decreases expression |
EXP |
2 |
30,889,817 |
30,891,837 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases cleavage |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases cleavage |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp7 |
caspase 7 |
|
increases activity |
ISO |
1 |
262,689,300 |
262,721,591 |
RGD:6480464 |
CTD |
| G |
Casp7 |
caspase 7 |
|
multiple interactions |
ISO |
1 |
262,689,300 |
262,721,591 |
RGD:6480464 |
CTD |
| G |
Cck |
cholecystokinin |
|
decreases expression |
ISO |
8 |
126,492,636 |
126,499,220 |
RGD:6480464 |
CTD |
| G |
Cck |
cholecystokinin |
|
decreases expression |
EXP |
8 |
126,492,636 |
126,499,220 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
decreases secretion |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl5 |
chemokine (C-C motif) ligand 5 |
|
multiple interactions |
ISO |
10 |
71,605,791 |
71,610,330 |
RGD:6480464 |
CTD |
| G |
Ccna2 |
cyclin A2 |
|
decreases expression |
ISO |
2 |
123,062,752 |
123,069,085 |
RGD:6480464 |
CTD |
| G |
Ccnb1 |
cyclin B1 |
|
decreases expression |
ISO |
2 |
31,574,600 |
31,581,784 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
decreases expression |
ISO |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
increases expression |
EXP |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
multiple interactions |
EXP |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd3 |
cyclin D3 |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ccne1 |
cyclin E1 |
|
decreases expression |
ISO |
1 |
90,568,189 |
90,577,426 |
RGD:6480464 |
CTD |
| G |
Ccne1 |
cyclin E1 |
|
multiple interactions |
ISO |
1 |
90,568,189 |
90,577,426 |
RGD:6480464 |
CTD |
| G |
Ccne1 |
cyclin E1 |
|
affects expression |
ISO |
1 |
90,568,189 |
90,577,426 |
RGD:6480464 |
CTD |
| G |
Cd8a |
CD8a molecule |
|
increases expression |
ISO |
4 |
104,589,922 |
104,594,159 |
RGD:6480464 |
CTD |
| G |
Cdk5 |
cyclin-dependent kinase 5 |
|
decreases expression |
ISO |
4 |
6,119,704 |
6,124,186 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
multiple interactions |
ISO |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
affects expression |
ISO |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
increases expression |
ISO |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
|
increases expression |
ISO |
4 |
171,841,705 |
171,846,506 |
RGD:6480464 |
CTD |
| G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
|
multiple interactions |
ISO |
4 |
171,841,705 |
171,846,506 |
RGD:6480464 |
CTD |
| G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
|
affects expression |
ISO |
4 |
171,841,705 |
171,846,506 |
RGD:6480464 |
CTD |
| G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
|
increases expression |
ISO |
5 |
108,908,749 |
108,916,380 |
RGD:6480464 |
CTD |
| G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) |
|
increases expression |
ISO |
5 |
108,939,669 |
108,945,293 |
RGD:6480464 |
CTD |
| G |
Chrna5 |
cholinergic receptor, nicotinic, alpha 5 (neuronal) |
|
decreases expression |
EXP |
8 |
58,538,002 |
58,566,388 |
RGD:6480464 |
CTD |
| G |
Chrnb4 |
cholinergic receptor, nicotinic, beta 4 (neuronal) |
|
decreases expression |
EXP |
8 |
58,586,961 |
58,605,545 |
RGD:6480464 |
CTD |
| G |
Cks1b |
CDC28 protein kinase regulatory subunit 1B |
|
multiple interactions |
ISO |
2 |
181,611,639 |
181,616,222 |
RGD:6480464 |
CTD |
| G |
Cks1b |
CDC28 protein kinase regulatory subunit 1B |
|
decreases expression |
ISO |
2 |
181,611,639 |
181,616,222 |
RGD:6480464 |
CTD |
| G |
Cnksr2 |
connector enhancer of kinase suppressor of Ras 2 |
|
decreases expression |
EXP |
X |
58,198,352 |
58,440,335 |
RGD:6480464 |
CTD |
| G |
Cnr1 |
cannabinoid receptor 1 (brain) |
|
multiple interactions |
EXP |
5 |
50,427,173 |
50,445,471 |
RGD:6480464 |
CTD |
| G |
Cnr1 |
cannabinoid receptor 1 (brain) |
|
decreases expression |
EXP |
5 |
50,427,173 |
50,445,471 |
RGD:6480464 |
CTD |
| G |
Creb1 |
cAMP responsive element binding protein 1 |
|
increases expression |
EXP |
9 |
63,170,785 |
63,234,727 |
RGD:6480464 |
CTD |
| G |
Creb1 |
cAMP responsive element binding protein 1 |
|
increases phosphorylation |
EXP |
9 |
63,170,785 |
63,234,727 |
RGD:6480464 |
CTD |
| G |
Creb1 |
cAMP responsive element binding protein 1 |
|
multiple interactions |
EXP |
9 |
63,170,785 |
63,234,727 |
RGD:6480464 |
CTD |
| G |
Creb1 |
cAMP responsive element binding protein 1 |
|
multiple interactions |
ISO |
9 |
63,170,785 |
63,234,727 |
RGD:6480464 |
CTD |
| G |
Creb1 |
cAMP responsive element binding protein 1 |
|
multiple interactions |
ISO |
9 |
63,170,785 |
63,234,727 |
RGD:6480464 |
CTD |
| G |
Creb1 |
cAMP responsive element binding protein 1 |
|
multiple interactions |
EXP |
9 |
63,170,785 |
63,234,727 |
RGD:6480464 |
CTD |
| G |
Creb1 |
cAMP responsive element binding protein 1 |
|
increases expression |
ISO |
9 |
63,170,785 |
63,234,727 |
RGD:6480464 |
CTD |
| G |
Creb1 |
cAMP responsive element binding protein 1 |
|
multiple interactions |
EXP |
9 |
63,170,785 |
63,234,727 |
RGD:6480464 |
CTD |
| G |
Creb1 |
cAMP responsive element binding protein 1 |
|
multiple interactions |
EXP |
9 |
63,170,785 |
63,234,727 |
RGD:6480464 |
CTD |
| G |
Creb1 |
cAMP responsive element binding protein 1 |
|
increases phosphorylation |
EXP |
9 |
63,170,785 |
63,234,727 |
RGD:6480464 |
CTD |
| G |
Crh |
corticotropin releasing hormone |
|
decreases expression |
ISO |
2 |
104,764,023 |
104,765,887 |
RGD:6480464 |
CTD |
| G |
Crh |
corticotropin releasing hormone |
|
decreases expression |
EXP |
2 |
104,764,023 |
104,765,887 |
RGD:6480464 |
CTD |
| G |
Crh |
corticotropin releasing hormone |
|
increases expression |
EXP |
2 |
104,764,023 |
104,765,887 |
RGD:6480464 |
CTD |
| G |
Crhr1 |
corticotropin releasing hormone receptor 1 |
|
increases expression |
EXP |
10 |
93,312,405 |
93,354,229 |
RGD:6480464 |
CTD |
| G |
Cry1 |
cryptochrome 1 (photolyase-like) |
|
affects expression |
ISO |
7 |
20,643,879 |
20,709,216 |
RGD:6480464 |
CTD |
| G |
Cry2 |
cryptochrome 2 (photolyase-like) |
|
decreases expression |
ISO |
3 |
76,802,782 |
76,830,902 |
RGD:6480464 |
CTD |
| G |
Ctnnb1 |
catenin (cadherin associated protein), beta 1 |
|
multiple interactions |
EXP |
8 |
125,978,161 |
125,987,670 |
RGD:6480464 |
CTD |
| G |
Ctnnb1 |
catenin (cadherin associated protein), beta 1 |
|
multiple interactions |
EXP |
8 |
125,978,161 |
125,987,670 |
RGD:6480464 |
CTD |
| G |
Ctsk |
cathepsin K |
|
multiple interactions |
ISO |
2 |
190,394,854 |
190,405,668 |
RGD:6480464 |
CTD |
| G |
Cxcl10 |
chemokine (C-X-C motif) ligand 10 |
|
decreases secretion |
ISO |
14 |
17,265,986 |
17,268,183 |
RGD:6480464 |
CTD |
| G |
Cyp26b1 |
cytochrome P450, family 26, subfamily b, polypeptide 1 |
|
decreases expression |
EXP |
4 |
118,734,786 |
118,751,606 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
multiple interactions |
EXP |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
affects abundance |
ISO |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
affects abundance |
ISO |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
increases metabolic processing |
ISO |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
|
multiple interactions |
EXP |
1 |
243,859,015 |
243,896,003 |
RGD:6480464 |
CTD |
| G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
|
decreases activity |
ISO |
1 |
244,400,004 |
244,493,624 |
RGD:6480464 |
CTD |
| G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
|
multiple interactions |
ISO |
1 |
244,400,004 |
244,493,624 |
RGD:6480464 |
CTD |
| G |
Cyp2d2 |
cytochrome P450, family 2, subfamily d, polypeptide 2 |
|
multiple interactions |
EXP |
7 |
120,796,210 |
120,800,279 |
RGD:6480464 |
CTD |
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
affects abundance |
ISO |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
affects metabolic processing |
ISO |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
decreases activity |
ISO |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
decreases metabolic processing |
ISO |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
affects abundance |
ISO |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
affects metabolic processing |
ISO |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
affects response to substance |
ISO |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
increases metabolic processing |
ISO |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
multiple interactions |
ISO |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
decreases methylation |
ISO |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
affects metabolic processing |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
affects response to substance |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
decreases methylation |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
decreases activity |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
affects abundance |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
affects metabolic processing |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
affects abundance |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
decreases metabolic processing |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
increases metabolic processing |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
affects metabolic processing |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
multiple interactions |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
increases metabolic processing |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
|
multiple interactions |
ISO |
12 |
17,164,384 |
17,204,589 |
RGD:6480464 |
CTD |
| G |
Dab1 |
Dab, reelin signal transducer, homolog 1 (Drosophila) |
|
increases expression |
EXP |
5 |
125,434,133 |
125,694,562 |
RGD:6480464 |
CTD |
| G |
Dap |
death-associated protein |
|
increases expression |
EXP |
2 |
83,281,937 |
83,335,284 |
RGD:6480464 |
CTD |
| G |
Dbh |
dopamine beta-hydroxylase (dopamine beta-monooxygenase) |
|
multiple interactions |
ISO |
3 |
6,052,706 |
6,069,826 |
RGD:6480464 |
CTD |
| G |
Dbh |
dopamine beta-hydroxylase (dopamine beta-monooxygenase) |
|
increases response to substance |
ISO |
3 |
6,052,706 |
6,069,826 |
RGD:6480464 |
CTD |
| G |
Dbh |
dopamine beta-hydroxylase (dopamine beta-monooxygenase) |
|
increases expression |
EXP |
3 |
6,052,706 |
6,069,826 |
RGD:6480464 |
CTD |
| G |
Dclk1 |
doublecortin-like kinase 1 |
|
increases expression |
EXP |
2 |
144,678,222 |
144,754,237 |
RGD:6480464 |
CTD |
| G |
Ddn |
dendrin |
|
decreases expression |
EXP |
7 |
137,572,548 |
137,576,530 |
RGD:6480464 |
CTD |
| G |
Dio3 |
deiodinase, iodothyronine, type III |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Dio3 |
deiodinase, iodothyronine, type III |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Dio3 |
deiodinase, iodothyronine, type III |
|
increases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Dnaja2 |
DnaJ (Hsp40) homolog, subfamily A, member 2 |
|
decreases expression |
EXP |
19 |
22,853,702 |
22,871,846 |
RGD:6480464 |
CTD |
| G |
Dnajb9 |
DnaJ (Hsp40) homolog, subfamily B, member 9 |
|
increases expression |
EXP |
6 |
63,583,033 |
63,587,247 |
RGD:6480464 |
CTD |
| G |
Drd2 |
dopamine receptor D2 |
|
decreases expression |
EXP |
8 |
52,641,160 |
52,707,749 |
RGD:6480464 |
CTD |
| G |
Drd3 |
dopamine receptor D3 |
|
multiple interactions |
ISO |
11 |
58,446,901 |
58,520,589 |
RGD:6480464 |
CTD |
| G |
Dusp8 |
dual specificity phosphatase 8 |
|
increases expression |
EXP |
1 |
202,215,086 |
202,229,746 |
RGD:6480464 |
CTD |
| G |
Eef2 |
eukaryotic translation elongation factor 2 |
|
increases phosphorylation |
EXP |
7 |
10,017,061 |
10,022,331 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
increases phosphorylation |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
multiple interactions |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
multiple interactions |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egr1 |
early growth response 1 |
|
multiple interactions |
EXP |
18 |
27,343,919 |
27,346,117 |
RGD:6480464 |
CTD |
| G |
Egr1 |
early growth response 1 |
|
increases expression |
EXP |
18 |
27,343,919 |
27,346,117 |
RGD:6480464 |
CTD |
| G |
Egr1 |
early growth response 1 |
|
multiple interactions |
EXP |
18 |
27,343,919 |
27,346,117 |
RGD:6480464 |
CTD |
| G |
Egr3 |
early growth response 3 |
|
decreases expression |
EXP |
15 |
50,477,453 |
50,479,909 |
RGD:6480464 |
CTD |
| G |
Egr4 |
early growth response 4 |
|
decreases expression |
EXP |
4 |
119,765,289 |
119,767,612 |
RGD:6480464 |
CTD |
| G |
Eif4e |
eukaryotic translation initiation factor 4E |
|
increases phosphorylation |
EXP |
2 |
236,072,748 |
236,104,714 |
RGD:6480464 |
CTD |
| G |
Enam |
enamelin |
|
decreases expression |
ISO |
14 |
21,137,021 |
21,162,644 |
RGD:6480464 |
CTD |
| G |
Ephx4 |
epoxide hydrolase 4 |
|
decreases expression |
EXP |
14 |
2,902,381 |
2,932,820 |
RGD:6480464 |
CTD |
| G |
Fabp1 |
fatty acid binding protein 1, liver |
|
increases expression |
ISO |
4 |
104,412,200 |
104,415,981 |
RGD:6480464 |
CTD |
| G |
Fabp1 |
fatty acid binding protein 1, liver |
|
increases expression |
ISO |
4 |
104,412,200 |
104,415,981 |
RGD:6480464 |
CTD |
| G |
Fgf1 |
fibroblast growth factor 1 (acidic) |
|
increases expression |
EXP |
18 |
31,785,480 |
31,806,452 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
multiple interactions |
EXP |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fhl2 |
four and a half LIM domains 2 |
|
decreases expression |
EXP |
9 |
42,319,997 |
42,349,055 |
RGD:6480464 |
CTD |
| G |
Fmod |
fibromodulin |
|
decreases expression |
EXP |
13 |
46,987,714 |
46,998,331 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
decreases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
decreases expression |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
affects expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fosb |
FBJ osteosarcoma oncogene B |
|
increases expression |
ISO |
1 |
78,668,497 |
78,673,330 |
RGD:6480464 |
CTD |
| G |
Fosb |
FBJ osteosarcoma oncogene B |
|
multiple interactions |
ISO |
1 |
78,668,497 |
78,673,330 |
RGD:6480464 |
CTD |
| G |
Gabrd |
gamma-aminobutyric acid (GABA) A receptor, delta |
|
decreases expression |
EXP |
5 |
172,203,064 |
172,214,960 |
RGD:6480464 |
CTD |
| G |
Gad1 |
glutamate decarboxylase 1 |
|
increases expression |
EXP |
3 |
52,789,370 |
52,830,038 |
RGD:6480464 |
CTD |
| G |
Gad2 |
glutamate decarboxylase 2 |
|
increases expression |
EXP |
17 |
96,259,430 |
96,321,857 |
RGD:6480464 |
CTD |
| G |
Gad2 |
glutamate decarboxylase 2 |
|
decreases expression |
EXP |
17 |
96,259,430 |
96,321,857 |
RGD:6480464 |
CTD |
| G |
Gak |
cyclin G associated kinase |
|
decreases expression |
EXP |
14 |
1,630,890 |
1,710,373 |
RGD:6480464 |
CTD |
| G |
Gal |
galanin/GMAP prepropeptide |
|
increases expression |
ISO |
1 |
205,936,352 |
205,941,215 |
RGD:6480464 |
CTD |
| G |
Gap43 |
growth associated protein 43 |
|
decreases expression |
EXP |
11 |
59,989,085 |
60,083,971 |
RGD:6480464 |
CTD |
| G |
Gdnf |
glial cell derived neurotrophic factor |
|
increases expression |
EXP |
2 |
57,399,312 |
57,424,030 |
RGD:6480464 |
CTD |
| G |
Gdnf |
glial cell derived neurotrophic factor |
|
multiple interactions |
EXP |
2 |
57,399,312 |
57,424,030 |
RGD:6480464 |
CTD |
| G |
Gdpd3 |
glycerophosphodiester phosphodiesterase domain containing 3 |
|
increases expression |
ISO |
1 |
185,941,893 |
185,984,348 |
RGD:6480464 |
CTD |
| G |
Gdpd3 |
glycerophosphodiester phosphodiesterase domain containing 3 |
|
increases expression |
ISO |
1 |
185,941,893 |
185,984,348 |
RGD:6480464 |
CTD |
| G |
Gfap |
glial fibrillary acidic protein |
|
increases response to substance |
ISO |
10 |
92,059,881 |
92,068,555 |
RGD:6480464 |
CTD |
| G |
Gfap |
glial fibrillary acidic protein |
|
increases expression |
ISO |
10 |
92,059,881 |
92,068,555 |
RGD:6480464 |
CTD |
| G |
Gja1 |
gap junction protein, alpha 1 |
|
increases expression |
EXP |
20 |
35,409,815 |
35,422,262 |
RGD:6480464 |
CTD |
| G |
Glo1 |
glyoxalase 1 |
|
increases response to substance |
ISO |
20 |
8,900,984 |
8,919,001 |
RGD:6480464 |
CTD |
| G |
Gna12 |
guanine nucleotide binding protein (G protein) alpha 12 |
|
increases expression |
EXP |
12 |
14,275,708 |
14,354,843 |
RGD:6480464 |
CTD |
| G |
Gnai2 |
guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2 |
|
decreases expression |
EXP |
8 |
112,861,952 |
112,882,647 |
RGD:6480464 |
CTD |
| G |
Gnai2 |
guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2 |
|
multiple interactions |
ISO |
8 |
112,861,952 |
112,882,647 |
RGD:6480464 |
CTD |
| G |
Gnaq |
guanine nucleotide binding protein (G protein), q polypeptide |
|
increases expression |
EXP |
1 |
219,520,998 |
219,764,401 |
RGD:6480464 |
CTD |
| G |
Gnas |
GNAS complex locus |
|
increases expression |
EXP |
3 |
165,213,399 |
165,214,551 |
RGD:6480464 |
CTD |
| G |
Gnas |
GNAS complex locus |
|
decreases expression |
EXP |
3 |
165,213,399 |
165,214,551 |
RGD:6480464 |
CTD |
| G |
Gnb2 |
guanine nucleotide binding protein (G protein), beta polypeptide 2 |
|
decreases expression |
ISO |
12 |
19,597,312 |
19,602,329 |
RGD:6480464 |
CTD |
| G |
Gpatch4 |
G patch domain containing 4 |
|
increases expression |
EXP |
2 |
180,123,437 |
180,132,225 |
RGD:6480464 |
CTD |
| G |
Gpd1 |
glycerol-3-phosphate dehydrogenase 1 (soluble) |
|
increases expression |
EXP |
7 |
138,458,875 |
138,466,266 |
RGD:6480464 |
CTD |
| G |
Gpx3 |
glutathione peroxidase 3 |
|
increases expression |
EXP |
10 |
40,311,094 |
40,319,382 |
RGD:6480464 |
CTD |
| G |
Gramd3 |
GRAM domain containing 3 |
|
increases expression |
EXP |
18 |
52,171,662 |
52,271,700 |
RGD:6480464 |
CTD |
| G |
Gria1 |
glutamate receptor, ionotropic, AMPA 1 |
|
affects expression |
EXP |
10 |
42,613,359 |
42,616,610 |
RGD:6480464 |
CTD |
| G |
Gria1 |
glutamate receptor, ionotropic, AMPA 1 |
|
multiple interactions |
ISO |
10 |
42,613,359 |
42,616,610 |
RGD:6480464 |
CTD |
| G |
Gria1 |
glutamate receptor, ionotropic, AMPA 1 |
|
affects phosphorylation |
ISO |
10 |
42,613,359 |
42,616,610 |
RGD:6480464 |
CTD |
| G |
Gria2 |
glutamate receptor, ionotropic, AMPA 2 |
|
increases expression |
EXP |
2 |
172,265,155 |
172,385,285 |
RGD:6480464 |
CTD |
| G |
Grik2 |
glutamate receptor, ionotropic, kainate 2 |
|
multiple interactions |
ISO |
20 |
53,231,473 |
53,713,131 |
RGD:6480464 |
CTD |
| G |
Grik2 |
glutamate receptor, ionotropic, kainate 2 |
|
increases expression |
ISO |
20 |
53,231,473 |
53,713,131 |
RGD:6480464 |
CTD |
| G |
Grin2a |
glutamate receptor, ionotropic, N-methyl D-aspartate 2A |
|
increases expression |
EXP |
10 |
5,588,229 |
6,004,780 |
RGD:6480464 |
CTD |
| G |
Gsk3b |
glycogen synthase kinase 3 beta |
|
increases expression |
EXP |
11 |
64,284,731 |
64,428,698 |
RGD:6480464 |
CTD |
| G |
Hapln2 |
hyaluronan and proteoglycan link protein 2 |
|
decreases expression |
EXP |
2 |
180,104,684 |
180,110,113 |
RGD:6480464 |
CTD |
| G |
Hdac2 |
histone deacetylase 2 |
|
increases expression |
EXP |
20 |
41,162,093 |
41,186,492 |
RGD:6480464 |
CTD |
| G |
Hdac5 |
histone deacetylase 5 |
|
increases response to substance |
ISO |
10 |
91,266,512 |
91,277,705 |
RGD:6480464 |
CTD |
| G |
Hes1 |
hairy and enhancer of split 1 (Drosophila) |
|
increases expression |
EXP |
11 |
72,603,482 |
72,605,673 |
RGD:6480464 |
CTD |
| G |
Hes5 |
hairy and enhancer of split 5 (Drosophila) |
|
increases expression |
EXP |
5 |
171,763,869 |
171,764,636 |
RGD:6480464 |
CTD |
| G |
Hes5 |
hairy and enhancer of split 5 (Drosophila) |
|
increases expression |
EXP |
5 |
171,763,869 |
171,764,636 |
RGD:6480464 |
CTD |
| G |
Hes5 |
hairy and enhancer of split 5 (Drosophila) |
|
increases expression |
EXP |
5 |
171,763,869 |
171,764,636 |
RGD:6480464 |
CTD |
| G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) |
|
increases expression |
ISO |
2 |
51,737,090 |
51,754,583 |
RGD:6480464 |
CTD |
| G |
Hnrpd |
heterogeneous nuclear ribonucleoprotein D |
|
increases expression |
EXP |
14 |
10,917,674 |
10,935,989 |
RGD:6480464 |
CTD |
| G |
Homer1 |
homer homolog 1 (Drosophila) |
|
decreases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Hpcal1 |
hippocalcin-like 1 |
|
increases expression |
EXP |
6 |
41,458,062 |
41,576,771 |
RGD:6480464 |
CTD |
| G |
Hpn |
hepsin |
|
increases expression |
ISO |
1 |
86,145,615 |
86,161,091 |
RGD:6480464 |
CTD |
| G |
Hpx |
hemopexin |
|
decreases expression |
EXP |
1 |
163,319,509 |
163,327,017 |
RGD:6480464 |
CTD |
| G |
Hrh1 |
histamine receptor H 1 |
|
multiple interactions |
ISO |
4 |
150,431,239 |
150,432,699 |
RGD:6480464 |
CTD |
| G |
Hspb8 |
heat shock protein B8 |
|
increases expression |
EXP |
12 |
41,407,166 |
41,421,565 |
RGD:6480464 |
CTD |
| G |
Htr1a |
5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled |
|
multiple interactions |
ISO |
2 |
36,434,518 |
36,435,786 |
RGD:6480464 |
CTD |
| G |
Htr1a |
5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled |
|
increases expression |
ISO |
2 |
36,434,518 |
36,435,786 |
RGD:6480464 |
CTD |
| G |
Htr1a |
5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled |
|
multiple interactions |
EXP |
2 |
36,434,518 |
36,435,786 |
RGD:6480464 |
CTD |
| G |
Htr1a |
5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled |
|
increases response to substance |
EXP |
2 |
36,434,518 |
36,435,786 |
RGD:6480464 |
CTD |
| G |
Htr1a |
5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled |
|
affects response to substance |
ISO |
2 |
36,434,518 |
36,435,786 |
RGD:6480464 |
CTD |
| G |
Htr1a |
5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled |
|
increases response to substance |
ISO |
2 |
36,434,518 |
36,435,786 |
RGD:6480464 |
CTD |
| G |
Htr1a |
5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled |
|
multiple interactions |
EXP |
2 |
36,434,518 |
36,435,786 |
RGD:6480464 |
CTD |
| G |
Htr1a |
5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled |
|
increases response to substance |
ISO |
2 |
36,434,518 |
36,435,786 |
RGD:6480464 |
CTD |
| G |
Htr1a |
5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled |
|
multiple interactions |
EXP |
2 |
36,434,518 |
36,435,786 |
RGD:6480464 |
CTD |
| G |
Htr1a |
5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled |
|
decreases expression |
EXP |
2 |
36,434,518 |
36,435,786 |
RGD:6480464 |
CTD |
| G |
Htr1b |
5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled |
|
decreases expression |
EXP |
8 |
86,700,088 |
86,701,248 |
RGD:6480464 |
CTD |
| G |
Htr1b |
5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled |
|
decreases expression |
EXP |
8 |
86,700,088 |
86,701,248 |
RGD:6480464 |
CTD |
| G |
Htr1b |
5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled |
|
increases expression |
EXP |
8 |
86,700,088 |
86,701,248 |
RGD:6480464 |
CTD |
| G |
Htr2a |
5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled |
|
affects response to substance |
ISO |
15 |
55,463,743 |
55,532,293 |
RGD:6480464 |
CTD |
| G |
Htr2a |
5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled |
|
increases expression |
ISO |
15 |
55,463,743 |
55,532,293 |
RGD:6480464 |
CTD |
| G |
Htr2a |
5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled |
|
decreases activity |
ISO |
15 |
55,463,743 |
55,532,293 |
RGD:6480464 |
CTD |
| G |
Htr2a |
5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled |
|
decreases activity |
ISO |
15 |
55,463,743 |
55,532,293 |
RGD:6480464 |
CTD |
| G |
Htr2b |
5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled |
|
increases expression |
ISO |
9 |
84,840,026 |
84,852,984 |
RGD:6480464 |
CTD |
| G |
Htr2b |
5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled |
|
multiple interactions |
ISO |
9 |
84,840,026 |
84,852,984 |
RGD:6480464 |
CTD |
| G |
Htr2b |
5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled |
|
multiple interactions |
ISO |
9 |
84,840,026 |
84,852,984 |
RGD:6480464 |
CTD |
| G |
Htr2b |
5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled |
|
multiple interactions |
ISO |
9 |
84,840,026 |
84,852,984 |
RGD:6480464 |
CTD |
| G |
Htr2b |
5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled |
|
increases activity |
ISO |
9 |
84,840,026 |
84,852,984 |
RGD:6480464 |
CTD |
| G |
Htr2b |
5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled |
|
multiple interactions |
ISO |
9 |
84,840,026 |
84,852,984 |
RGD:6480464 |
CTD |
| G |
Htr2c |
5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled |
|
affects binding |
ISO |
X |
31,012,921 |
31,244,127 |
RGD:6480464 |
CTD |
| G |
Htr2c |
5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled |
|
increases expression |
ISO |
X |
31,012,921 |
31,244,127 |
RGD:6480464 |
CTD |
| G |
Htr2c |
5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled |
|
multiple interactions |
EXP |
X |
31,012,921 |
31,244,127 |
RGD:6480464 |
CTD |
| G |
Htr2c |
5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled |
|
multiple interactions |
ISO |
X |
31,012,921 |
31,244,127 |
RGD:6480464 |
CTD |
| G |
Htr2c |
5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled |
|
multiple interactions |
EXP |
X |
31,012,921 |
31,244,127 |
RGD:6480464 |
CTD |
| G |
Htr2c |
5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled |
|
increases expression |
ISO |
X |
31,012,921 |
31,244,127 |
RGD:6480464 |
CTD |
| G |
Icam5 |
intercellular adhesion molecule 5, telencephalin |
|
decreases expression |
EXP |
8 |
20,055,255 |
20,062,100 |
RGD:6480464 |
CTD |
| G |
Ifna1 |
interferon, alpha 1 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
increases expression |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Igf2 |
insulin-like growth factor 2 |
|
decreases expression |
EXP |
1 |
202,906,624 |
202,915,231 |
RGD:6480464 |
CTD |
| G |
Igfbp2 |
insulin-like growth factor binding protein 2 |
|
decreases expression |
EXP |
9 |
71,966,877 |
71,994,211 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
decreases expression |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases expression |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Inhbe |
inhibin beta E |
|
increases expression |
ISO |
7 |
67,308,713 |
67,310,138 |
RGD:6480464 |
CTD |
| G |
Inhbe |
inhibin beta E |
|
increases expression |
ISO |
7 |
67,308,713 |
67,310,138 |
RGD:6480464 |
CTD |
| G |
Inhbe |
inhibin beta E |
|
increases expression |
ISO |
7 |
67,308,713 |
67,310,138 |
RGD:6480464 |
CTD |
| G |
Insig1 |
insulin induced gene 1 |
|
increases expression |
EXP |
4 |
2,577,468 |
2,585,682 |
RGD:6480464 |
CTD |
| G |
Itgam |
integrin, alpha M |
|
multiple interactions |
ISO |
1 |
187,334,413 |
187,385,583 |
RGD:6480464 |
CTD |
| G |
Itpka |
inositol-trisphosphate 3-kinase A |
|
decreases expression |
EXP |
3 |
106,257,482 |
106,266,160 |
RGD:6480464 |
CTD |
| G |
Jag1 |
jagged 1 |
|
increases expression |
EXP |
3 |
125,181,063 |
125,216,481 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
decreases expression |
ISO |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
decreases expression |
ISO |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Kcna3 |
potassium voltage-gated channel, shaker-related subfamily, member 3 |
|
decreases activity |
ISO |
2 |
202,472,638 |
202,474,215 |
RGD:6480464 |
CTD |
| G |
Kcna5 |
potassium voltage-gated channel, shaker-related subfamily, member 5 |
|
increases expression |
EXP |
4 |
162,896,283 |
162,898,091 |
RGD:6480464 |
CTD |
| G |
Kcna6 |
potassium voltage gated channel, shaker related subfamily, member 6 |
|
decreases expression |
EXP |
4 |
163,087,398 |
163,125,320 |
RGD:6480464 |
CTD |
| G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
|
multiple interactions |
ISO |
4 |
6,192,644 |
6,224,285 |
RGD:6480464 |
CTD |
| G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
|
affects localization |
ISO |
4 |
6,192,644 |
6,224,285 |
RGD:6480464 |
CTD |
| G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
|
decreases activity |
ISO |
4 |
6,192,644 |
6,224,285 |
RGD:6480464 |
CTD |
| G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
|
affects response to substance |
ISO |
4 |
6,192,644 |
6,224,285 |
RGD:6480464 |
CTD |
| G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
|
multiple interactions |
ISO |
4 |
6,192,644 |
6,224,285 |
RGD:6480464 |
CTD |
| G |
Kcnj3 |
potassium inwardly-rectifying channel, subfamily J, member 3 |
|
multiple interactions |
ISO |
3 |
37,068,672 |
37,256,990 |
RGD:6480464 |
CTD |
| G |
Kcnj4 |
potassium inwardly-rectifying channel, subfamily J, member 4 |
|
multiple interactions |
ISO |
7 |
117,601,723 |
117,616,019 |
RGD:6480464 |
CTD |
| G |
Kcnj5 |
potassium inwardly-rectifying channel, subfamily J, member 5 |
|
multiple interactions |
ISO |
8 |
32,082,866 |
32,104,412 |
RGD:6480464 |
CTD |
| G |
Kcnj6 |
potassium inwardly-rectifying channel, subfamily J, member 6 |
|
multiple interactions |
ISO |
11 |
35,025,118 |
35,116,500 |
RGD:6480464 |
CTD |
| G |
Kcnk10 |
potassium channel, subfamily K, member 10 |
|
affects response to substance |
ISO |
6 |
122,600,156 |
122,729,583 |
RGD:6480464 |
CTD |
| G |
Kcnk10 |
potassium channel, subfamily K, member 10 |
|
multiple interactions |
ISO |
6 |
122,600,156 |
122,729,583 |
RGD:6480464 |
CTD |
| G |
Kcnk10 |
potassium channel, subfamily K, member 10 |
|
decreases activity |
ISO |
6 |
122,600,156 |
122,729,583 |
RGD:6480464 |
CTD |
| G |
Kcnk10 |
potassium channel, subfamily K, member 10 |
|
increases expression |
ISO |
6 |
122,600,156 |
122,729,583 |
RGD:6480464 |
CTD |
| G |
Kcnk2 |
potassium channel, subfamily K, member 2 |
|
multiple interactions |
EXP |
13 |
105,376,001 |
105,574,238 |
RGD:6480464 |
CTD |
| G |
Kcnk2 |
potassium channel, subfamily K, member 2 |
|
decreases expression |
EXP |
13 |
105,376,001 |
105,574,238 |
RGD:6480464 |
CTD |
| G |
Kcnk2 |
potassium channel, subfamily K, member 2 |
|
decreases response to substance |
EXP |
13 |
105,376,001 |
105,574,238 |
RGD:6480464 |
CTD |
| G |
Kcnk2 |
potassium channel, subfamily K, member 2 |
|
decreases expression |
ISO |
13 |
105,376,001 |
105,574,238 |
RGD:6480464 |
CTD |
| G |
Kcnk2 |
potassium channel, subfamily K, member 2 |
|
affects response to substance |
ISO |
13 |
105,376,001 |
105,574,238 |
RGD:6480464 |
CTD |
| G |
Kcnk2 |
potassium channel, subfamily K, member 2 |
|
decreases activity |
ISO |
13 |
105,376,001 |
105,574,238 |
RGD:6480464 |
CTD |
| G |
Kcnk2 |
potassium channel, subfamily K, member 2 |
|
multiple interactions |
ISO |
13 |
105,376,001 |
105,574,238 |
RGD:6480464 |
CTD |
| G |
Kcnv1 |
potassium channel, subfamily V, member 1 |
|
decreases expression |
EXP |
7 |
81,012,246 |
81,018,587 |
RGD:6480464 |
CTD |
| G |
Klf10 |
Kruppel-like factor 10 |
|
increases expression |
EXP |
7 |
73,821,190 |
73,826,866 |
RGD:6480464 |
CTD |
| G |
L1cam |
L1 cell adhesion molecule |
|
multiple interactions |
EXP |
X |
159,784,792 |
159,801,553 |
RGD:6480464 |
CTD |
| G |
L1cam |
L1 cell adhesion molecule |
|
increases expression |
EXP |
X |
159,784,792 |
159,801,553 |
RGD:6480464 |
CTD |
| G |
Lmna |
lamin A/C |
|
decreases expression |
EXP |
2 |
180,595,724 |
180,616,354 |
RGD:6480464 |
CTD |
| G |
LOC500300 |
similar to hypothetical protein MGC6835 |
|
increases expression |
ISO |
4 |
153,000,782 |
153,002,562 |
RGD:6480464 |
CTD |
| G |
LOC500300 |
similar to hypothetical protein MGC6835 |
|
increases expression |
ISO |
4 |
153,000,782 |
153,002,562 |
RGD:6480464 |
CTD |
| G |
LOC500300 |
similar to hypothetical protein MGC6835 |
|
increases expression |
ISO |
4 |
153,000,782 |
153,002,562 |
RGD:6480464 |
CTD |
| G |
Lrg1 |
leucine-rich alpha-2-glycoprotein 1 |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Lss |
lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase) |
|
increases expression |
ISO |
20 |
12,507,575 |
12,534,612 |
RGD:6480464 |
CTD |
| G |
Map1b |
microtubule-associated protein 1B |
|
increases expression |
EXP |
2 |
30,415,235 |
30,508,354 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
decreases expression |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
decreases phosphorylation |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
increases phosphorylation |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
increases phosphorylation |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
increases expression |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk14 |
mitogen activated protein kinase 14 |
|
increases phosphorylation |
ISO |
20 |
6,939,249 |
7,000,378 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
decreases phosphorylation |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
increases expression |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
increases phosphorylation |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
EXP |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
EXP |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
increases phosphorylation |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
increases expression |
EXP |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
decreases expression |
EXP |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Mbd1 |
methyl-CpG binding domain protein 1 |
|
increases expression |
EXP |
18 |
71,068,257 |
71,082,734 |
RGD:6480464 |
CTD |
| G |
Mc4r |
melanocortin 4 receptor |
|
decreases expression |
EXP |
18 |
63,390,922 |
63,392,809 |
RGD:6480464 |
CTD |
| G |
Mcpt1 |
mast cell protease 1 |
|
decreases expression |
EXP |
15 |
34,270,481 |
34,273,035 |
RGD:6480464 |
CTD |
| G |
Mecp2 |
methyl CpG binding protein 2 |
|
increases expression |
EXP |
X |
159,980,599 |
160,035,260 |
RGD:6480464 |
CTD |
| G |
Mif |
macrophage migration inhibitory factor (glycosylation-inhibiting factor) |
|
affects response to substance |
EXP |
20 |
13,191,986 |
13,192,851 |
RGD:6480464 |
CTD |
| G |
Mmp20 |
matrix metallopeptidase 20 |
|
decreases expression |
ISO |
8 |
4,467,263 |
4,507,865 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
multiple interactions |
ISO |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
decreases activity |
EXP |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Mtor |
mechanistic target of rapamycin (serine/threonine kinase) |
|
multiple interactions |
EXP |
5 |
165,531,402 |
165,640,899 |
RGD:6480464 |
CTD |
| G |
Myc |
myelocytomatosis oncogene |
|
decreases phosphorylation |
ISO |
7 |
98,953,142 |
98,958,060 |
RGD:6480464 |
CTD |
| G |
Ncam1 |
neural cell adhesion molecule 1 |
|
increases expression |
EXP |
8 |
52,822,350 |
53,120,572 |
RGD:6480464 |
CTD |
| G |
Neurod2 |
neuronal differentiation 2 |
|
decreases expression |
EXP |
10 |
87,097,850 |
87,111,300 |
RGD:6480464 |
CTD |
| G |
Nf1 |
neurofibromin 1 |
|
decreases expression |
ISO |
10 |
65,574,833 |
65,766,305 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
ISO |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
increases expression |
EXP |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Ngfr |
nerve growth factor receptor |
|
increases response to substance |
ISO |
10 |
84,262,804 |
84,281,006 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
increases expression |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Notch1 |
notch 1 |
|
increases expression |
EXP |
3 |
4,631,797 |
4,677,640 |
RGD:6480464 |
CTD |
| G |
Nov |
nephroblastoma overexpressed |
|
decreases expression |
EXP |
7 |
91,162,676 |
91,169,696 |
RGD:6480464 |
CTD |
| G |
Npas2 |
neuronal PAS domain protein 2 |
|
affects expression |
ISO |
9 |
38,255,362 |
38,434,352 |
RGD:6480464 |
CTD |
| G |
Nptx2 |
neuronal pentraxin II |
|
increases expression |
EXP |
12 |
10,359,406 |
10,370,315 |
RGD:6480464 |
CTD |
| G |
Npy |
neuropeptide Y |
|
increases expression |
ISO |
4 |
78,038,013 |
78,045,187 |
RGD:6480464 |
CTD |
| G |
Npy |
neuropeptide Y |
|
decreases expression |
EXP |
4 |
78,038,013 |
78,045,187 |
RGD:6480464 |
CTD |
| G |
Npy |
neuropeptide Y |
|
affects expression |
EXP |
4 |
78,038,013 |
78,045,187 |
RGD:6480464 |
CTD |
| G |
Npy |
neuropeptide Y |
|
decreases secretion |
EXP |
4 |
78,038,013 |
78,045,187 |
RGD:6480464 |
CTD |
| G |
Npy1r |
neuropeptide Y receptor Y1 |
|
affects expression |
EXP |
16 |
24,747,183 |
24,756,507 |
RGD:6480464 |
CTD |
| G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
|
increases expression |
ISO |
5 |
151,524,685 |
151,528,000 |
RGD:6480464 |
CTD |
| G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
|
increases expression |
ISO |
5 |
151,524,685 |
151,528,000 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
multiple interactions |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
affects response to substance |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
decreases expression |
EXP |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
increases expression |
EXP |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
decreases expression |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
multiple interactions |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
increases expression |
EXP |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
|
decreases expression |
EXP |
19 |
32,527,752 |
32,875,369 |
RGD:6480464 |
CTD |
| G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
|
multiple interactions |
EXP |
19 |
32,527,752 |
32,875,369 |
RGD:6480464 |
CTD |
| G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
|
increases expression |
EXP |
19 |
32,527,752 |
32,875,369 |
RGD:6480464 |
CTD |
| G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
|
increases expression |
EXP |
19 |
32,527,752 |
32,875,369 |
RGD:6480464 |
CTD |
| G |
Nr4a2 |
nuclear receptor subfamily 4, group A, member 2 |
|
decreases expression |
ISO |
3 |
38,866,205 |
38,871,678 |
RGD:6480464 |
CTD |
| G |
Nr4a3 |
nuclear receptor subfamily 4, group A, member 3 |
|
decreases expression |
EXP |
5 |
64,713,468 |
64,753,311 |
RGD:6480464 |
CTD |
| G |
Nrgn |
neurogranin |
|
decreases expression |
EXP |
8 |
38,790,596 |
38,799,077 |
RGD:6480464 |
CTD |
| G |
Nrn1 |
neuritin 1 |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ntrk2 |
neurotrophic tyrosine kinase, receptor, type 2 |
|
increases expression |
EXP |
17 |
11,494,463 |
11,811,654 |
RGD:6480464 |
CTD |
| G |
Ntrk2 |
neurotrophic tyrosine kinase, receptor, type 2 |
|
increases expression |
EXP |
17 |
11,494,463 |
11,811,654 |
RGD:6480464 |
CTD |
| G |
Ntrk2 |
neurotrophic tyrosine kinase, receptor, type 2 |
|
increases expression |
EXP |
17 |
11,494,463 |
11,811,654 |
RGD:6480464 |
CTD |
| G |
Ntrk2 |
neurotrophic tyrosine kinase, receptor, type 2 |
|
multiple interactions |
ISO |
17 |
11,494,463 |
11,811,654 |
RGD:6480464 |
CTD |
| G |
Ntrk2 |
neurotrophic tyrosine kinase, receptor, type 2 |
|
increases phosphorylation |
ISO |
17 |
11,494,463 |
11,811,654 |
RGD:6480464 |
CTD |
| G |
Nucb1 |
nucleobindin 1 |
|
affects expression |
EXP |
1 |
95,961,163 |
95,981,910 |
RGD:6480464 |
CTD |
| G |
Nupr1 |
nuclear protein, transcriptional regulator, 1 |
|
increases expression |
ISO |
1 |
185,770,310 |
185,772,313 |
RGD:6480464 |
CTD |
| G |
Nupr1 |
nuclear protein, transcriptional regulator, 1 |
|
increases expression |
ISO |
1 |
185,770,310 |
185,772,313 |
RGD:6480464 |
CTD |
| G |
Nupr1 |
nuclear protein, transcriptional regulator, 1 |
|
increases expression |
ISO |
1 |
185,770,310 |
185,772,313 |
RGD:6480464 |
CTD |
| G |
Olig2 |
oligodendrocyte lineage transcription factor 2 |
|
increases expression |
ISO |
11 |
31,205,416 |
31,208,792 |
RGD:6480464 |
CTD |
| G |
Oprm1 |
opioid receptor, mu 1 |
|
multiple interactions |
ISO |
1 |
37,535,416 |
37,779,392 |
RGD:6480464 |
CTD |
| G |
Oprm1 |
opioid receptor, mu 1 |
|
increases expression |
EXP |
1 |
37,535,416 |
37,779,392 |
RGD:6480464 |
CTD |
| G |
Oxt |
oxytocin/neurophysin 1 prepropeptide |
|
decreases expression |
EXP |
3 |
118,194,219 |
118,195,056 |
RGD:6480464 |
CTD |
| G |
Oxtr |
oxytocin receptor |
|
multiple interactions |
EXP |
4 |
148,314,089 |
148,326,797 |
RGD:6480464 |
CTD |
| G |
Oxtr |
oxytocin receptor |
|
increases expression |
EXP |
4 |
148,314,089 |
148,326,797 |
RGD:6480464 |
CTD |
| G |
P4hb |
prolyl 4-hydroxylase, beta polypeptide |
|
increases expression |
EXP |
10 |
109,950,221 |
109,961,716 |
RGD:6480464 |
CTD |
| G |
Paqr8 |
progestin and adipoQ receptor family member VIII |
|
increases expression |
EXP |
9 |
19,661,028 |
19,678,009 |
RGD:6480464 |
CTD |
| G |
Pde4a |
phosphodiesterase 4A, cAMP-specific |
|
increases expression |
EXP |
8 |
20,192,677 |
20,241,557 |
RGD:6480464 |
CTD |
| G |
Pde4b |
phosphodiesterase 4B, cAMP specific |
|
decreases expression |
EXP |
5 |
123,158,156 |
123,533,877 |
RGD:6480464 |
CTD |
| G |
Pde4b |
phosphodiesterase 4B, cAMP specific |
|
increases expression |
EXP |
5 |
123,158,156 |
123,533,877 |
RGD:6480464 |
CTD |
| G |
Pde4b |
phosphodiesterase 4B, cAMP specific |
|
affects expression |
EXP |
5 |
123,158,156 |
123,533,877 |
RGD:6480464 |
CTD |
| G |
Pde4d |
phosphodiesterase 4D, cAMP-specific |
|
affects expression |
EXP |
2 |
40,196,097 |
41,311,012 |
RGD:6480464 |
CTD |
| G |
Pde8b |
phosphodiesterase 8B |
|
increases expression |
EXP |
2 |
25,352,725 |
25,469,209 |
RGD:6480464 |
CTD |
| G |
Pdyn |
prodynorphin |
|
affects expression |
EXP |
3 |
117,291,025 |
117,303,367 |
RGD:6480464 |
CTD |
| G |
Pdyn |
prodynorphin |
|
decreases expression |
EXP |
3 |
117,291,025 |
117,303,367 |
RGD:6480464 |
CTD |
| G |
Penk |
proenkephalin |
|
decreases expression |
EXP |
5 |
17,509,323 |
17,514,265 |
RGD:6480464 |
CTD |
| G |
Per1 |
period circadian clock 1 |
|
decreases expression |
ISO |
10 |
55,859,851 |
55,868,747 |
RGD:6480464 |
CTD |
| G |
Per2 |
period circadian clock 2 |
|
affects expression |
ISO |
9 |
90,645,342 |
90,687,509 |
RGD:6480464 |
CTD |
| G |
Pla2g4a |
phospholipase A2, group IVA (cytosolic, calcium-dependent) |
|
multiple interactions |
EXP |
13 |
64,135,729 |
64,280,815 |
RGD:6480464 |
CTD |
| G |
Pla2g4a |
phospholipase A2, group IVA (cytosolic, calcium-dependent) |
|
multiple interactions |
ISO |
13 |
64,135,729 |
64,280,815 |
RGD:6480464 |
CTD |
| G |
Pla2g4a |
phospholipase A2, group IVA (cytosolic, calcium-dependent) |
|
increases expression |
ISO |
13 |
64,135,729 |
64,280,815 |
RGD:6480464 |
CTD |
| G |
Plcb1 |
phospholipase C, beta 1 (phosphoinositide-specific) |
|
decreases expression |
EXP |
3 |
122,797,718 |
123,523,675 |
RGD:6480464 |
CTD |
| G |
Plec |
plectin |
|
decreases expression |
EXP |
7 |
114,202,742 |
114,262,385 |
RGD:6480464 |
CTD |
| G |
Pmch |
pro-melanin-concentrating hormone |
|
decreases expression |
EXP |
7 |
24,778,133 |
24,779,449 |
RGD:6480464 |
CTD |
| G |
Pomc |
proopiomelanocortin |
|
increases expression |
EXP |
6 |
26,931,969 |
26,937,789 |
RGD:6480464 |
CTD |
| G |
Pomc |
proopiomelanocortin |
|
decreases expression |
EXP |
6 |
26,931,969 |
26,937,789 |
RGD:6480464 |
CTD |
| G |
Ppp1r1b |
protein phosphatase 1, regulatory (inhibitor) subunit 1B |
|
affects phosphorylation |
ISO |
10 |
87,121,889 |
87,131,587 |
RGD:6480464 |
CTD |
| G |
Ppp1r1b |
protein phosphatase 1, regulatory (inhibitor) subunit 1B |
|
increases expression |
ISO |
10 |
87,121,889 |
87,131,587 |
RGD:6480464 |
CTD |
| G |
Ppp1r1b |
protein phosphatase 1, regulatory (inhibitor) subunit 1B |
|
multiple interactions |
ISO |
10 |
87,121,889 |
87,131,587 |
RGD:6480464 |
CTD |
| G |
Ppp1r1b |
protein phosphatase 1, regulatory (inhibitor) subunit 1B |
|
increases response to substance |
ISO |
10 |
87,121,889 |
87,131,587 |
RGD:6480464 |
CTD |
| G |
Prkcg |
protein kinase C, gamma |
|
decreases expression |
EXP |
1 |
64,145,749 |
64,172,712 |
RGD:6480464 |
CTD |
| G |
Prkg1 |
protein kinase, cGMP-dependent, type 1 |
|
multiple interactions |
EXP |
1 |
234,420,597 |
235,765,375 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
multiple interactions |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
increases expression |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
increases expression |
EXP |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
increases expression |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prss23 |
protease, serine, 23 |
|
decreases expression |
EXP |
1 |
146,081,552 |
146,089,928 |
RGD:6480464 |
CTD |
| G |
Psma3 |
proteasome (prosome, macropain) subunit, alpha type 3 |
|
affects expression |
EXP |
6 |
93,092,191 |
93,112,167 |
RGD:6480464 |
CTD |
| G |
Psmb4 |
proteasome (prosome, macropain) subunit, beta type 4 |
|
decreases expression |
EXP |
2 |
189,778,476 |
189,781,169 |
RGD:6480464 |
CTD |
| G |
Pter |
phosphotriesterase related |
|
decreases expression |
EXP |
17 |
87,212,759 |
87,275,527 |
RGD:6480464 |
CTD |
| G |
Ptgds |
prostaglandin D2 synthase (brain) |
|
decreases expression |
ISO |
3 |
3,632,683 |
3,635,617 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
decreases expression |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
decreases expression |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
decreases expression |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptk2b |
protein tyrosine kinase 2 beta |
|
decreases expression |
EXP |
15 |
45,589,222 |
45,717,866 |
RGD:6480464 |
CTD |
| G |
Qrfpr |
pyroglutamylated RFamide peptide receptor |
|
decreases expression |
EXP |
2 |
122,677,072 |
122,719,991 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
increases activity |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Reln |
reelin |
|
increases expression |
EXP |
4 |
8,150,873 |
8,609,141 |
RGD:6480464 |
CTD |
| G |
Rgs3 |
regulator of G-protein signaling 3 |
|
increases expression |
EXP |
5 |
79,624,388 |
79,709,035 |
RGD:6480464 |
CTD |
| G |
Rprml |
reprimo-like |
|
decreases expression |
EXP |
10 |
92,804,937 |
92,805,941 |
RGD:6480464 |
CTD |
| G |
S100b |
S100 calcium binding protein B |
|
increases response to substance |
ISO |
20 |
12,791,440 |
12,824,508 |
RGD:6480464 |
CTD |
| G |
S100b |
S100 calcium binding protein B |
|
increases expression |
ISO |
20 |
12,791,440 |
12,824,508 |
RGD:6480464 |
CTD |
| G |
S100b |
S100 calcium binding protein B |
|
increases expression |
ISO |
20 |
12,791,440 |
12,824,508 |
RGD:6480464 |
CTD |
| G |
S100b |
S100 calcium binding protein B |
|
increases expression |
EXP |
20 |
12,791,440 |
12,824,508 |
RGD:6480464 |
CTD |
| G |
Samd4a |
sterile alpha motif domain containing 4A |
|
decreases expression |
EXP |
15 |
22,847,701 |
22,952,499 |
RGD:6480464 |
CTD |
| G |
Scd |
stearoyl-CoA desaturase (delta-9-desaturase) |
|
increases expression |
ISO |
1 |
249,358,105 |
249,371,164 |
RGD:6480464 |
CTD |
| G |
Serpina3n |
serine (or cysteine) peptidase inhibitor, clade A, member 3N |
|
increases expression |
ISO |
6 |
128,461,775 |
128,469,309 |
RGD:6480464 |
CTD |
| G |
Serpina3n |
serine (or cysteine) peptidase inhibitor, clade A, member 3N |
|
increases expression |
ISO |
6 |
128,461,775 |
128,469,309 |
RGD:6480464 |
CTD |
| G |
Serpina3n |
serine (or cysteine) peptidase inhibitor, clade A, member 3N |
|
increases expression |
ISO |
6 |
128,461,775 |
128,469,309 |
RGD:6480464 |
CTD |
| G |
Serpini1 |
serpin peptidase inhibitor, clade I (neuroserpin), member 1 |
|
increases expression |
EXP |
2 |
166,445,765 |
166,555,032 |
RGD:6480464 |
CTD |
| G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
|
increases expression |
EXP |
1 |
23,501,257 |
23,506,651 |
RGD:6480464 |
CTD |
| G |
Slc13a4 |
solute carrier family 13 (sodium/sulfate symporters), member 4 |
|
decreases expression |
EXP |
4 |
62,679,593 |
62,724,547 |
RGD:6480464 |
CTD |
| G |
Slc17a7 |
solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 7 |
|
increases expression |
ISO |
1 |
95,640,743 |
95,651,938 |
RGD:6480464 |
CTD |
| G |
Slc17a7 |
solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 7 |
|
decreases expression |
EXP |
1 |
95,640,743 |
95,651,938 |
RGD:6480464 |
CTD |
| G |
Slc2a3 |
solute carrier family 2 (facilitated glucose transporter), member 3 |
|
decreases expression |
ISO |
4 |
159,210,116 |
159,221,169 |
RGD:6480464 |
CTD |
| G |
Slc2a3 |
solute carrier family 2 (facilitated glucose transporter), member 3 |
|
decreases expression |
ISO |
4 |
159,210,116 |
159,221,169 |
RGD:6480464 |
CTD |
| G |
Slc30a3 |
solute carrier family 30 (zinc transporter), member 3 |
|
decreases expression |
EXP |
6 |
25,257,765 |
25,264,794 |
RGD:6480464 |
CTD |
| G |
Slc32a1 |
solute carrier family 32 (GABA vesicular transporter), member 1 |
|
decreases expression |
EXP |
3 |
149,342,399 |
149,347,124 |
RGD:6480464 |
CTD |
| G |
Slc6a3 |
solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
|
multiple interactions |
ISO |
1 |
30,516,568 |
30,557,540 |
RGD:6480464 |
CTD |
| G |
Slc6a3 |
solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
|
affects response to substance |
ISO |
1 |
30,516,568 |
30,557,540 |
RGD:6480464 |
CTD |
| G |
Slc6a4 |
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
|
affects response to substance |
ISO |
10 |
67,134,790 |
67,155,891 |
RGD:6480464 |
CTD |
| G |
Slc6a4 |
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
|
increases expression |
ISO |
10 |
67,134,790 |
67,155,891 |
RGD:6480464 |
CTD |
| G |
Slc6a4 |
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
|
multiple interactions |
EXP |
10 |
67,134,790 |
67,155,891 |
RGD:6480464 |
CTD |
| G |
Slc6a4 |
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
|
decreases expression |
EXP |
10 |
67,134,790 |
67,155,891 |
RGD:6480464 |
CTD |
| G |
Slc6a4 |
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
|
decreases localization |
ISO |
10 |
67,134,790 |
67,155,891 |
RGD:6480464 |
CTD |
| G |
Slc6a4 |
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
|
increases response to substance |
ISO |
10 |
67,134,790 |
67,155,891 |
RGD:6480464 |
CTD |
| G |
Slc6a4 |
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
|
affects response to substance |
ISO |
10 |
67,134,790 |
67,155,891 |
RGD:6480464 |
CTD |
| G |
Slc6a4 |
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
|
decreases expression |
EXP |
10 |
67,134,790 |
67,155,891 |
RGD:6480464 |
CTD |
| G |
Slc6a4 |
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
|
multiple interactions |
EXP |
10 |
67,134,790 |
67,155,891 |
RGD:6480464 |
CTD |
| G |
Slc6a4 |
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
|
decreases expression |
EXP |
10 |
67,134,790 |
67,155,891 |
RGD:6480464 |
CTD |
| G |
Slc6a4 |
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
|
multiple interactions |
EXP |
10 |
67,134,790 |
67,155,891 |
RGD:6480464 |
CTD |
| G |
Slc6a4 |
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
|
multiple interactions |
ISO |
10 |
67,134,790 |
67,155,891 |
RGD:6480464 |
CTD |
| G |
Slc6a4 |
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
|
decreases expression |
EXP |
10 |
67,134,790 |
67,155,891 |
RGD:6480464 |
CTD |
| G |
Slc6a4 |
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
|
affects expression |
ISO |
10 |
67,134,790 |
67,155,891 |
RGD:6480464 |
CTD |
| G |
Slc6a4 |
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
|
decreases expression |
EXP |
10 |
67,134,790 |
67,155,891 |
RGD:6480464 |
CTD |
| G |
Slc6a4 |
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
|
increases response to substance |
ISO |
10 |
67,134,790 |
67,155,891 |
RGD:6480464 |
CTD |
| G |
Slc6a4 |
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
|
decreases response to substance |
ISO |
10 |
67,134,790 |
67,155,891 |
RGD:6480464 |
CTD |
| G |
Slc6a4 |
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
|
decreases activity |
ISO |
10 |
67,134,790 |
67,155,891 |
RGD:6480464 |
CTD |
| G |
Smad1 |
SMAD family member 1 |
|
multiple interactions |
EXP |
19 |
30,348,886 |
30,409,345 |
RGD:6480464 |
CTD |
| G |
Snd1 |
staphylococcal nuclease and tudor domain containing 1 |
|
increases expression |
EXP |
4 |
55,350,745 |
55,761,185 |
RGD:6480464 |
CTD |
| G |
Sqle |
squalene epoxidase |
|
decreases expression |
EXP |
7 |
96,096,897 |
96,111,772 |
RGD:6480464 |
CTD |
| G |
Sqstm1 |
sequestosome 1 |
|
decreases expression |
ISO |
10 |
35,751,300 |
35,762,630 |
RGD:6480464 |
CTD |
| G |
Srsf5 |
serine/arginine-rich splicing factor 5 |
|
affects expression |
EXP |
6 |
104,728,286 |
104,732,982 |
RGD:6480464 |
CTD |
| G |
Stc1 |
stanniocalcin 1 |
|
increases expression |
EXP |
15 |
49,566,885 |
49,577,539 |
RGD:6480464 |
CTD |
| G |
Stxbp1 |
syntaxin binding protein 1 |
|
increases expression |
EXP |
3 |
11,762,105 |
11,825,531 |
RGD:6480464 |
CTD |
| G |
Syn1 |
synapsin I |
|
increases expression |
EXP |
X |
12,512,241 |
12,556,160 |
RGD:6480464 |
CTD |
| G |
Syp |
synaptophysin |
|
increases expression |
EXP |
X |
26,890,307 |
26,905,319 |
RGD:6480464 |
CTD |
| G |
Syp |
synaptophysin |
|
decreases expression |
ISO |
X |
26,890,307 |
26,905,319 |
RGD:6480464 |
CTD |
| G |
Tagln |
transgelin |
|
decreases expression |
ISO |
8 |
48,902,208 |
48,907,682 |
RGD:6480464 |
CTD |
| G |
Tagln |
transgelin |
|
decreases expression |
ISO |
8 |
48,902,208 |
48,907,682 |
RGD:6480464 |
CTD |
| G |
Tagln |
transgelin |
|
decreases expression |
ISO |
8 |
48,902,208 |
48,907,682 |
RGD:6480464 |
CTD |
| G |
Th |
tyrosine hydroxylase |
|
decreases expression |
ISO |
1 |
203,164,253 |
203,171,506 |
RGD:6480464 |
CTD |
| G |
Th |
tyrosine hydroxylase |
|
increases expression |
EXP |
1 |
203,164,253 |
203,171,506 |
RGD:6480464 |
CTD |
| G |
Th |
tyrosine hydroxylase |
|
increases expression |
ISO |
1 |
203,164,253 |
203,171,506 |
RGD:6480464 |
CTD |
| G |
Th |
tyrosine hydroxylase |
|
decreases expression |
EXP |
1 |
203,164,253 |
203,171,506 |
RGD:6480464 |
CTD |
| G |
Th |
tyrosine hydroxylase |
|
increases expression |
EXP |
1 |
203,164,253 |
203,171,506 |
RGD:6480464 |
CTD |
| G |
Tmc4 |
transmembrane channel-like 4 |
|
decreases expression |
EXP |
1 |
63,852,716 |
63,864,605 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases activity |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnfsf11 |
tumor necrosis factor (ligand) superfamily, member 11 |
|
multiple interactions |
ISO |
15 |
59,397,837 |
59,428,014 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
increases expression |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
increases expression |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tph1 |
tryptophan hydroxylase 1 |
|
increases expression |
ISO |
1 |
97,186,071 |
97,207,551 |
RGD:6480464 |
CTD |
| G |
Tph1 |
tryptophan hydroxylase 1 |
|
increases expression |
EXP |
1 |
97,186,071 |
97,207,551 |
RGD:6480464 |
CTD |
| G |
Tph2 |
tryptophan hydroxylase 2 |
|
increases expression |
EXP |
7 |
54,321,033 |
54,430,706 |
RGD:6480464 |
CTD |
| G |
Tph2 |
tryptophan hydroxylase 2 |
|
multiple interactions |
EXP |
7 |
54,321,033 |
54,430,706 |
RGD:6480464 |
CTD |
| G |
Tph2 |
tryptophan hydroxylase 2 |
|
decreases expression |
EXP |
7 |
54,321,033 |
54,430,706 |
RGD:6480464 |
CTD |
| G |
Tph2 |
tryptophan hydroxylase 2 |
|
affects response to substance |
ISO |
7 |
54,321,033 |
54,430,706 |
RGD:6480464 |
CTD |
| G |
Tph2 |
tryptophan hydroxylase 2 |
|
increases expression |
ISO |
7 |
54,321,033 |
54,430,706 |
RGD:6480464 |
CTD |
| G |
Tph2 |
tryptophan hydroxylase 2 |
|
decreases expression |
EXP |
7 |
54,321,033 |
54,430,706 |
RGD:6480464 |
CTD |
| G |
Tph2 |
tryptophan hydroxylase 2 |
|
affects expression |
EXP |
7 |
54,321,033 |
54,430,706 |
RGD:6480464 |
CTD |
| G |
Tph2 |
tryptophan hydroxylase 2 |
|
affects expression |
ISO |
7 |
54,321,033 |
54,430,706 |
RGD:6480464 |
CTD |
| G |
Tph2 |
tryptophan hydroxylase 2 |
|
increases response to substance |
EXP |
7 |
54,321,033 |
54,430,706 |
RGD:6480464 |
CTD |
| G |
Tph2 |
tryptophan hydroxylase 2 |
|
decreases expression |
EXP |
7 |
54,321,033 |
54,430,706 |
RGD:6480464 |
CTD |
| G |
Tpm1 |
tropomyosin 1, alpha |
|
decreases expression |
EXP |
8 |
71,331,304 |
71,358,063 |
RGD:6480464 |
CTD |
| G |
Tshb |
thyroid stimulating hormone, beta |
|
increases expression |
EXP |
2 |
197,908,308 |
197,913,186 |
RGD:6480464 |
CTD |
| G |
Tssk2 |
testis-specific serine kinase 2 |
|
decreases expression |
EXP |
11 |
85,074,711 |
85,076,066 |
RGD:6480464 |
CTD |
| G |
Ttr |
transthyretin |
|
increases expression |
ISO |
18 |
12,406,571 |
12,413,680 |
RGD:6480464 |
CTD |
| G |
Tubb3 |
tubulin, beta 3 class III |
|
decreases expression |
ISO |
19 |
53,742,652 |
53,751,706 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
increases expression |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vgf |
VGF nerve growth factor inducible |
|
increases expression |
ISO |
12 |
20,903,304 |
20,906,327 |
RGD:6480464 |
CTD |
| G |
Vldlr |
very low density lipoprotein receptor |
|
increases expression |
EXP |
1 |
230,666,736 |
230,697,748 |
RGD:6480464 |
CTD |
| G |
Wfs1 |
Wolfram syndrome 1 (wolframin) |
|
decreases expression |
EXP |
14 |
79,379,680 |
79,404,003 |
RGD:6480464 |
CTD |
| G |
Wipi1 |
WD repeat domain, phosphoinositide interacting 1 |
|
increases expression |
ISO |
10 |
98,722,266 |
98,753,713 |
RGD:6480464 |
CTD |
| G |
Wipi1 |
WD repeat domain, phosphoinositide interacting 1 |
|
increases expression |
ISO |
10 |
98,722,266 |
98,753,713 |
RGD:6480464 |
CTD |
| G |
Wipi1 |
WD repeat domain, phosphoinositide interacting 1 |
|
increases expression |
ISO |
10 |
98,722,266 |
98,753,713 |
RGD:6480464 |
CTD |
| G |
Wnt3a |
wingless-type MMTV integration site family, member 3A |
|
increases phosphorylation |
EXP |
10 |
45,553,682 |
45,594,983 |
RGD:6480464 |
CTD |
| G |
Xiap |
X-linked inhibitor of apoptosis |
|
increases expression |
EXP |
X |
3,011,520 |
3,047,798 |
RGD:6480464 |
CTD |
| G |
Xpo1 |
exportin 1, CRM1 homolog (yeast) |
|
decreases expression |
EXP |
14 |
103,943,249 |
103,978,717 |
RGD:6480464 |
CTD |
| G |
Xpo1 |
exportin 1, CRM1 homolog (yeast) |
|
increases expression |
EXP |
14 |
103,943,249 |
103,978,717 |
RGD:6480464 |
CTD |
| G |
Ywhae |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon polypeptide |
|
affects expression |
EXP |
10 |
63,072,128 |
63,109,833 |
RGD:6480464 |
CTD |
| G |
Ywhah |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta polypeptide |
|
affects expression |
EXP |
14 |
83,448,395 |
83,457,778 |
RGD:6480464 |
CTD |
| G |
Ywhaz |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide |
|
increases expression |
EXP |
7 |
72,283,825 |
72,306,126 |
RGD:6480464 |
CTD |
Term paths to the root
|